Travoprost 75 mcg · intracameral implant
Antiglaucoma, Injections & Implants
Approved uses
Open-angle glaucoma or ocular hypertension
A single travoprost implant administered intracamerally under aseptic conditions. It is not recommended to readminister iDose TR more than once per year.
Removes the daily-drop adherence problem for a prostaglandin, which is the usual reason pressure control fails
Contraindications
- Active or suspected ocular or periocular infection
- Corneal endothelial cell dystrophy
- Prior corneal transplantation or endothelial cell transplant, such as DSAEK
- Hypersensitivity to travoprost or any other component of the product
75 mcg travoprost intracameral implant, pre-loaded in a sterile single-dose inserter
Travoprost free acid, a prostaglandin analog is a selective FP prostanoid receptor agonist, which is believed to reduce IOP by increasing uveoscleral outflow. The exact mechanism of action is unknown at this time.
Warnings & Precautions
- Improper implant placement: use iDose TR with caution in narrow iridocorneal angles (Shaffer grade below 3) or other angle abnormalities, such as peripheral anterior synechia or rubeosis iridis, that could impair proper placement at the planned implantation site.
- Device dislocation: dislocation of the iDose TR has been observed in clinical trials. Monitor patients routinely to confirm the implant remains at the site of administration. If the implant becomes dislocated, it should be surgically removed.
- Corneal endothelial cell loss: readminister iDose TR with caution in eyes with 10% or greater loss in central corneal endothelial cell density from pre-administration baseline (adjusted for age-related 1% loss per year and for a 10% loss after an anterior segment surgical procedure, such as cataract surgery). Readministration is not recommended if baseline central corneal endothelial cell density was not established before the initial administration.
- Minimum corneal endothelial cell density: central corneal endothelial cell density should not be less than the recommended minimum before the initial administration and before each readministration. The minimum depends on age and lens status, from 2,200 cells/mm2 in phakic eyes at 45 years or younger to 1,120 cells/mm2 in pseudophakic eyes over 65 years.
- Pigmentation: topical ophthalmic travoprost has been reported to cause increased pigmentation to pigmented tissues. After discontinuation of travoprost, pigmentation of the iris is likely to be permanent, and iris color change may not be noticeable for several months to years. Patients who develop noticeably increased iris pigmentation should be examined regularly.
- Macular edema: macular edema, including cystoid macular edema, has been reported with ophthalmic travoprost, including iDose TR; use with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or with known risk factors for macular edema.
- Endophthalmitis: intraocular procedures and injections have been associated with endophthalmitis; always use proper aseptic technique and monitor patients after administration.
- MR Conditional: patients should inform their healthcare provider that they have an iDose TR implant before any MRI. A patient may be safely scanned only under the label's conditions, including a static magnetic field of 3.0 T or less. Failure to follow these conditions may result in injury to the patient.
- Intraocular inflammation: prostaglandin analogs, including iDose TR, have been reported to cause intraocular inflammation. Use with caution in active intraocular inflammation, such as uveitis, because it may worsen.
Common Side Effects
The most commonly reported ocular adverse reactions (2% to 6%) were increases in intraocular pressure, iritis, dry eye, visual field defects, eye pain, ocular hyperemia, and reduced visual acuity.
Pregnancy: There are no adequate and well-controlled studies of iDose TR in pregnant women. Subcutaneous travoprost given to pregnant mice and rats during organogenesis produced embryo-fetal lethality, spontaneous abortion, and premature delivery at potentially clinically relevant doses. Advise pregnant women of a potential risk to a fetus.
Lactation: Unknown whether travoprost is present in human milk.
The safety and effectiveness of iDose TR have not been established in pediatric patients.